let's be realistic..., page-29

IMO a Reddys buy out would definitely be at a price that's under valued in Reddy's eyes, however ACL and it's shareholders might think it's a fair deal. We all sit here arguing over earnings, expanding markets, and threat of other generic competition- Reddy's on the other hand need not argue, since their models have already accurately calculated how much Fonda is really worth. This isn't some inconstant Aussie bio company we're in partnership with... Reddys are arguably the best generic marketers/sellers/manufacturers in the world. IMO their value of Fonda might be alot higher than what the market is leading on......

There's also the question of how much more cost efficient is Reddy's manufacturing over GSK's. Is there a possibility Reddy's and GSK could go into partnership to take on the EU and other expanding markets? Remember Reddy's and GSK have done exactly this before.

Reddy's buying the EU rights to Fonda is what's most likely IMO